-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $75

Benzinga·11/10/2026 17:04:52
語音播報
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $104 to $75.